This case report describes a patient with non-dysplastic Barrett’s esophagus whose high-risk TissueCypher result prompted a six-month follow-up endoscopy, revealing high-grade dysplasia not identified during the initial evaluation. The patient subsequently underwent radiofrequency ablation and achieved complete eradication of intestinal metaplasia after two treatment sessions.

This decision modeling study used pooled data to compare Barrett’s esophagus management with and without TissueCypher guidance. Incorporating TissueCypher was projected to improve appropriate, risk-aligned management from 59.8% to 75.3% while reducing both undertreatment of patients who progressed and overtreatment of those who did not.

This real-world case series evaluated how TissueCypher results changed management in 90% of NDBE patients and influenced management or increased physician confidence in 97%, supporting risk-aligned escalation or de-escalation of care.

In this multi-center prospective study, the i31-SLNB accurately predicted SLN positivity, and patients who avoided SLNB based on i31-SLNB results had high RFS. Thus, the i31-SLNB identifies low-risk patients who may consider foregoing the SLNB procedure.

Atopic dermatitis (AD) is an inflammatory skin disease driven by complex biological interplay between type 1, 2, and 17 inflammatory processes. Systemic therapies, including biologics that target T helper type 2 inflammatory pathway (Th2-targeted therapies) and small molecules targeting multiple inflammatory pathways (JAK inhibitors, JAKi), have improved care for AD. However, current therapy selection is trial and error without consideration of each patient’s underlying biology, resulting in inadequate disease control for approximately 45% of patients taking systemic therapies for AD. An objective test to measure each patient’s underlying disease biology to guide therapy selection with the goal of reducing the trial-and-error phase of therapy selection should lead to earlier response to treatment and an improved proportion of patients who achieve adequate disease control. The objective of this study was to develop and validate a non-invasive gene expression profile (GEP) test to guide systemic therapy selection for AD to improve health outcomes.

This case series describes two patients with Barrett’s esophagus indefinite for dysplasia whose high-risk TissueCypher results prompted advanced imaging and earlier follow-up. Subsequent evaluation identified high-grade dysplasia in both patients—including intramucosal cancer in one—enabling timely intervention.

This rural community study evaluated TissueCypher-guided management in 114 patients with non-dysplastic Barrett’s esophagus. Test results influenced care in 93% of cases, supporting ablation for higher-risk patients and longer surveillance intervals for those at low risk.

This case series describes two patients with non-dysplastic Barrett’s esophagus whose high-risk TissueCypher results prompted earlier intervention. Both patients were subsequently found to have progressed to low-grade dysplasia, demonstrating how individualized risk stratification can support risk-aligned management.

This case report demonstrates the real-world utility of TissueCypher in three patients with Barrett’s esophagus who appeared clinically low risk. TissueCypher provided personalized risk information to help guide risk-aligned management decisions based on each patient’s likelihood of progression to high-grade dysplasia or esophageal adenocarcinoma.

This multicenter study evaluated TissueCypher risk stratification in 85 patients with non-dysplastic Barrett’s esophagus across four surgical practices. TissueCypher identified 15% as intermediate or high risk, revealing patients whose predicted progression risk was comparable to or greater than that associated with low-grade dysplasia.